This bill would create the “Menstrual Product Safety and Research Act” by adding a new section to the Public Health Law directing the Commissioner of Health to provide for research on the potential health risks associated with menstrual products. The research would examine whether substances such as dioxins, synthetic fibers, chlorine, fragrances, colorants, dyes, preservatives, and other contaminants in products like tampons, pads, liners, cups, sponges, douches, wipes, and sprays pose health risks to users.
The bill specifically calls for study of possible links to conditions including cervical cancer, endometriosis, infertility, ovarian cancer, breast cancer, immune system deficiencies, pelvic inflammatory disease, toxic shock syndrome, and bacterial and yeast infections. It also requires research into whether use of these products may affect the health of biological children born to people who used them during or before pregnancy, including fetal and childhood development outcomes. The department must also review and confirm data submitted by manufacturers to the U.S. Food and Drug Administration, complete the research within four years, and report findings and recommendations to state leaders and the public within one year after completion.
The bill would not directly regulate the composition or sale of menstrual products, but it would expand the Public Health Law by creating a temporary state research program focused on menstrual product safety. It would require the Department of Health to investigate potential toxic exposures and health outcomes, compare or confirm manufacturer-submitted data, and publish findings, which could inform future regulatory or legislative action. The act would take effect 90 days after enactment and expire five years later, making it a sunsetted research initiative rather than a permanent program.
Based on the bill text and the absence of recorded committee debate or votes, the measure appears to be framed as a public health and consumer safety initiative rather than a partisan or highly contentious regulatory proposal. Its sponsors present it as a precautionary research effort to better understand possible risks from menstrual products and to make the results public. With no voting history or transcript available, there is no documented opposition or support to gauge legislative sentiment beyond the bill’s preventive, health-focused purpose.
The main potential points of contention are the scope and scientific basis of the proposed research, especially the bill’s focus on a wide range of health conditions and on possible effects on pregnancies and children. Manufacturers of menstrual products could be concerned about scrutiny of ingredients and FDA-submitted data, while public health advocates may support the study as a response to uncertainty about product safety. Because there is no committee transcript or vote record, no specific member or stakeholder objections are documented in the available materials.